All AbMole products are for research use only, cannot be used for human consumption.
For this product's availability, delivery time and price, please email inquiry@abmole.com directly or click the "Inquiry Now" button below.
Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer.
| CAS Number | 1638338-43-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Related Notch Products |
|---|
| FLI-06
FLI-06 is a novel inhibitor of Notch signaling with EC50 of 2.3 μM. |
| LY900009
LY900009 is a potent, first-in-class Notch inhibitor with IC50 of 0.27 nM. |
| Tangeretin
Tangeretin is a flavonoid from citrus fruit peels, and is also selected as a Notch-1 inhibitor, which plays an important role in anti-inflammatory responses and neuroprotective effects in several disease models. |
| IMR-1
IMR-1 is a first-in-class, cell-permeable inhibitor of the Notch transcription activation complex, with an IC50 of 26 μM. IMR-1 prevents Maml1 from recruiting to the Notch ternary complex (NTC) in chromatin, inhibits transcription of Notch target genes, and has antitumor activity. |
| NVS-ZP7-4
NVS-ZP7-4 is a potent ZIP7 Inhibitor, which inhibits Notch signaling with IC50 of 0.13 uM in HES-Luc reporter gene assays, selectively induces apoptosis and ER stress. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
